KALA BIO (KALA) Competitors $3.77 -0.18 (-4.56%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$3.80 +0.03 (+0.90%) As of 05/21/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALA vs. GALT, VIRI, CRBP, LXEO, VTYX, ANIX, SNTI, ZURA, CLLS, and CLYMShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Galectin Therapeutics (GALT), Virios Therapeutics (VIRI), Corbus Pharmaceuticals (CRBP), Lexeo Therapeutics (LXEO), Ventyx Biosciences (VTYX), Anixa Biosciences (ANIX), Senti Biosciences (SNTI), Zura Bio (ZURA), Cellectis (CLLS), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Galectin Therapeutics Virios Therapeutics Corbus Pharmaceuticals Lexeo Therapeutics Ventyx Biosciences Anixa Biosciences Senti Biosciences Zura Bio Cellectis Climb Bio Galectin Therapeutics (NASDAQ:GALT) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Is GALT or KALA more profitable? Galectin Therapeutics' return on equity of 0.00% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Galectin TherapeuticsN/A N/A -163.15% KALA BIO N/A -448.61%-69.37% Do analysts recommend GALT or KALA? Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 759.38%. KALA BIO has a consensus target price of $15.00, indicating a potential upside of 297.88%. Given Galectin Therapeutics' higher possible upside, equities analysts plainly believe Galectin Therapeutics is more favorable than KALA BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, GALT or KALA? Galectin Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -1.91, meaning that its share price is 291% less volatile than the S&P 500. Does the media prefer GALT or KALA? In the previous week, Galectin Therapeutics had 3 more articles in the media than KALA BIO. MarketBeat recorded 3 mentions for Galectin Therapeutics and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.50 beat Galectin Therapeutics' score of 1.00 indicating that KALA BIO is being referred to more favorably in the news media. Company Overall Sentiment Galectin Therapeutics Positive KALA BIO Very Positive Do institutionals & insiders hold more shares of GALT or KALA? 11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by company insiders. Comparatively, 8.3% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in GALT or KALA? Galectin Therapeutics received 45 more outperform votes than KALA BIO when rated by MarketBeat users. However, 66.96% of users gave KALA BIO an outperform vote while only 59.01% of users gave Galectin Therapeutics an outperform vote. CompanyUnderperformOutperformGalectin TherapeuticsOutperform Votes34759.01% Underperform Votes24140.99% KALA BIOOutperform Votes30266.96% Underperform Votes14933.04% Which has stronger valuation & earnings, GALT or KALA? Galectin Therapeutics has higher earnings, but lower revenue than KALA BIO. Galectin Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalectin TherapeuticsN/AN/A-$41.07M-$0.72-1.78KALA BIO$3.89M6.25-$42.20M-$8.24-0.46 SummaryGalectin Therapeutics and KALA BIO tied by winning 8 of the 16 factors compared between the two stocks. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.32M$6.53B$5.38B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E Ratio-0.308.9226.8019.71Price / Sales6.25252.24389.55117.28Price / CashN/A65.8538.2534.62Price / Book1.356.466.804.50Net Income-$42.20M$143.98M$3.23B$248.18M7 Day Performance17.08%2.03%1.53%0.23%1 Month Performance28.23%4.11%10.05%12.39%1 Year Performance-42.35%-2.87%16.75%7.07% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO3.5208 of 5 stars$3.77-4.6%$15.00+297.9%-42.7%$24.32M$3.89M-0.3030Positive NewsGap UpGALTGalectin Therapeutics1.2326 of 5 stars$1.39+0.7%$11.00+691.4%-60.4%$87.82MN/A-1.909Earnings ReportGap UpVIRIVirios TherapeuticsN/A$4.56flat$3.00-34.2%+2,875.0%$87.82MN/A-16.895CRBPCorbus Pharmaceuticals4.5886 of 5 stars$7.16+11.0%$50.88+610.5%-83.6%$87.58MN/A-1.5340Positive NewsLXEOLexeo Therapeutics2.8455 of 5 stars$2.63-2.2%$22.20+744.1%-79.6%$87.31M$650,000.00-0.8358News CoverageAnalyst RevisionGap DownHigh Trading VolumeVTYXVentyx Biosciences2.2772 of 5 stars$1.21-2.4%$10.00+726.4%-67.7%$86.11MN/A-0.5130News CoveragePositive NewsGap DownANIXAnixa Biosciences1.7189 of 5 stars$2.66+1.9%$9.00+238.3%-6.2%$85.64M$210,000.00-6.825Gap UpSNTISenti Biosciences1.6894 of 5 stars$3.26flat$12.00+268.1%-14.7%$85.02M$2.56M-0.214ZURAZura Bio2.859 of 5 stars$1.24+2.5%$14.33+1,055.9%-81.3%$84.79MN/A-2.343News CoverageAnalyst RevisionGap UpCLLSCellectis2.763 of 5 stars$1.51-4.4%$7.00+363.6%-48.5%$83.93M$41.51M-1.16290CLYMClimb Bio2.5447 of 5 stars$1.24+4.2%$10.00+706.5%N/A$83.79MN/A-0.589Positive NewsAnalyst RevisionGap Up Related Companies and Tools Related Companies Galectin Therapeutics Competitors Virios Therapeutics Competitors Corbus Pharmaceuticals Competitors Lexeo Therapeutics Competitors Ventyx Biosciences Competitors Anixa Biosciences Competitors Senti Biosciences Competitors Zura Bio Competitors Cellectis Competitors Climb Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KALA Stock Free KALA Stock Alerts